← Leaderboards
Paul R Bohjanen
University Of Minnesota Twin Cities
$7,607,694
Attributed
$9,291,534
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,291,534 · 12
By mechanism
UM1$2,912,092 · 1
R01$2,603,642 · 2
K24$1,017,700 · 1
M01$685,042 · 1
R21$627,948 · 2
K02$539,055 · 1
Top collaborators
- David R Boulware3 shared
- Michael C Keefer2 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Jeffrey P. Kahn$3,238,569
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionClinical ResearchLaboratoriesCommunicable DiseasesGrantHiv InfectionsAfrica South Of The SaharaAfricaAntiretroviral TherapyDiagnosisAcquired Immunodeficiency SyndromeUgandaBaseUniversitiesProgramsCryptococcal MeningitisImmuneInflammatoryCellsInflammatory ResponseCohort StudiesEventIncidenceImmune System
Grant awards (38)
University of Rochester HIV/AIDS Clinical Trials Unit$1,817,383
UM1 · FY2025 · AI
University of Rochester HIV/AIDS Clinical Trials Unit Administrative Supplement$1,094,709
UM1 · FY2025 · AI
Etiology and Outcomes of Meningitis in Rural, Northern Uganda$162,592
R21 · FY2023 · TW · contact PI
Etiology and Outcomes of Meningitis in Rural, Northern Uganda$189,768
R21 · FY2022 · TW · contact PI
Outcomes of Cryptococcal Meningitis in Uganda$203,540
K24 · FY2015 · AI · contact PI
Outcomes of Cryptococcal Meningitis in Uganda$203,540
K24 · FY2014 · AI · contact PI
Outcomes of Cryptococcal Meningitis in Uganda$203,540
K24 · FY2013 · AI · contact PI
Outcomes of Cryptococcal Meningitis in Uganda$203,540
K24 · FY2012 · AI · contact PI
Novel Regulators of T Cell mRNA Decay$325,669
R01 · FY2011 · AI · contact PI
Outcomes of Cryptococcal Meningitis in Uganda$203,540
K24 · FY2011 · AI · contact PI
Impact of HIV and HIV therapy on the Etiology and Outcome of Meningitis in Uganda$130,091
R21 · FY2011 · NS
Novel Regulators of T Cell mRNA Decay$329,010
R01 · FY2010 · AI · contact PI
Impact of HIV and HIV therapy on the Etiology and Outcome of Meningitis in Uganda$145,497
R21 · FY2010 · NS
Novel Regulators of T Cell mRNA Decay$14,917
R01 · FY2010 · AI · contact PI
Novel Regulators of T Cell mRNA Decay$332,384
R01 · FY2009 · AI · contact PI
Trial for the Optimal Timing of HIV Therapy after Cryptococcal Meningitis$180,000
R34 · FY2009 · AI
HIV Immune Reconstitution Inflammatory Syndrome in Uganda$75,500
R03 · FY2009 · AI · contact PI
Novel Regulators of T Cell mRNA Decay$332,434
R01 · FY2008 · AI · contact PI
HIV Immune Reconstitution Inflammatory Syndrome in Uganda$75,500
R03 · FY2008 · AI · contact PI
mRNA Decay in T Lymphocyte Activation$324,495
R56 · FY2006 · AI · contact PI
Regulation of T Lymphocyte mRNA Degradation$107,811
K02 · FY2006 · AI · contact PI
Regulation of T Lymphocyte mRNA Degradation$107,811
K02 · FY2005 · AI
RNA-BP in Regulation of T Lymphocyte Activation$255,963
R01 · FY2004 · AI
Regulation of T Lymphocyte mRNA Degradation$107,811
K02 · FY2004 · AI
RNA-BP in Regulation of T Lymphocyte Activation$255,999
R01 · FY2003 · AI
Regulation of T Lymphocyte mRNA Degradation$107,811
K02 · FY2003 · AI
RNA-BP in Regulation of T Lymphocyte Activation$220,894
R01 · FY2002 · AI
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$117,022
M01 · FY2002 · RR
Regulation of T Lymphocyte mRNA Degradation$107,811
K02 · FY2002 · AI
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$293,069
M01 · FY2001 · RR
RNA-BP in Regulation of T Lymphocyte Activation$256,069
R01 · FY2001 · AI
TAR RNA AND REGULATING HIV1 TRANSCRIPTION$125,280
K08 · FY2001 · AI
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$117,022
M01 · FY2001 · RR
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$117,022
M01 · FY2001 · RR
RNA-BP in Regulation of T Lymphocyte Activation$280,303
R01 · FY2000 · AI
TAR RNA AND REGULATING HIV1 TRANSCRIPTION$125,280
K08 · FY2000 · AI
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$40,907
M01 · FY2000 · RR
AMBULATORY PERITONEAL DIALYSIS--PHARMACOKINETICS OF LAMIVUDINE IN HIV$0
M01 · FY2000 · RR